KRAS and colorectal carcinoma: However, the proliferation and migration of WT-KRAS CRC cells were decreased after treatment with cetuximab while these abilities remained unchanged in circIFNGR2 overexpressed cells regardless of cetuximab treatment (Fig. 6a–c).